Welcome to our dedicated page for TOMI Environmental Solutions news (Ticker: TOMZ), a resource for investors and traders seeking the latest updates and insights on TOMI Environmental Solutions stock.
TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global leader in bacteria decontamination and infectious disease control. The company provides advanced environmental solutions for indoor surface decontamination through the manufacturing, sales, service, and licensing of its premier Binary Ionization Technology® (BIT™) platform, marketed under the SteraMist® brand.
TOMI's BIT™ platform, developed in collaboration with the Defense Advanced Research Projects Agency (DARPA) and a major U.S. defense contractor, was initially created to address chemical and biological threats following the 2001 anthrax attacks. The technology utilizes a patented two-step process that activates and ionizes a 7.8% hydrogen peroxide solution to produce a disinfectant mist or fog. This innovation ensures effective sterilization while being safe for use on various materials, including delicate electronics.
The SteraMist® product line includes the SteraMist Surface Unit, SteraMist Environment System, SteraMist Total Disinfection Cart, SteraMist Select Surface Unit, Stainless Steel 90 Degree Applicator, iHP Plasma Decontamination Chamber, SteraMist Custom Engineered System (CES), and iHP Corporate Service Decontamination. These products serve diverse sectors such as hospitals, biosafety labs, pharmaceutical facilities, commercial buildings, schools, and more.
Recently, TOMI conducted a successful study that demonstrated the efficacy of its SteraMist® iHP technology in eliminating the Foot-and-Mouth Disease Virus (FMDV) from both porous and non-porous surfaces. This study, performed under EPA standards, highlights TOMI's commitment to food safety and combating Transboundary Animal Disease (TAD) outbreaks.
In 2023, TOMI expanded its sales infrastructure by onboarding additional distributors and sales representatives, enhancing its domestic and international presence. The company is also focusing on diversifying its product line with innovations like the SteraMist® Hybrid, Transport, and Select Plus units. These efforts are expected to drive revenue growth and strengthen TOMI's market position.
Financially, TOMI has shown resilience despite challenges, with substantial growth in its sales pipeline and backlog. The company is also engaging in significant government relationships and receiving notable orders from sectors like pharmaceuticals and homeland security. These developments are poised to boost TOMI's revenue and market footprint.
TOMI is also committed to cost reduction initiatives to align its cost structure with profitability goals. The company expects a 30% reduction in operational cash use by the end of 2024, aiming for long-term shareholder value while maintaining innovation and growth momentum.
For more information, visit www.steramist.com or contact us at info@tomimist.com.
TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) announced preliminary unaudited revenue for Q2 2024. Revenue is expected to be approximately $3.0 million, a 10% increase year-over-year and a 170% increase sequentially. BIT Solution sales are projected to rise by about 31% year-over-year and 171% sequentially.
CEO Dr. Halden Shane attributes this growth to successful expansion of sales channels and customer base. The company's Custom Engineered Systems (CES) and SteraMist Hybrid solution are driving long-term growth. TOMI expects continued growth in the second half of 2024, aligning with analyst estimates. Full Q2 results are expected to be announced in early August 2024.
TOMI Environmental Solutions (NASDAQ: TOMZ) has secured a $1.2 million contract with Enviro-Mist Inc., a division of EMAQ Group, for the purchase of 20 SteraMist Environment Systems. This revenue will be recognized in Q2 2024. Enviro-Mist has joined TOMI's iHP Corporate Service team as an exclusive partner for the pharmaceutical market in the Western United States.
The partnership includes a multi-year contract for a single location of a long-standing customer, estimated to generate approximately $60,000 in annual BIT Solution sales. This strategic alliance aims to enhance SteraMist iHP technology's market penetration in the pharmaceutical industry, positioning TOMI for large-scale service sales and increased industry presence.
TOMI Environmental Solutions (NASDAQ: TOMZ) is collaborating with partners to combat the global avian influenza (H5N1) outbreak. Announced on June 13, 2024, the outbreak has affected 48 states and 50 jurisdictions, posing significant risks to poultry, dairy farms, and public health. TOMI's Binary Ionization Technology (BIT) and SteraMist products are being utilized to mitigate the spread of the virus. The company sees this as a strategic opportunity for growth in the food safety and agricultural sectors. CEO Dr. Halden Shane emphasizes the importance of advanced disinfection methods and biosecurity measures to ensure business continuity and animal health.
TOMI Environmental Solutions (NASDAQ: TOMZ) announced two new purchase agreements with leading pharmaceutical companies. The first agreement involves a SteraMist Environment System and validation services for a major private pharmaceutical company in Mexico, marking an expansion of TOMI's global operations. The second agreement includes the sale of a SteraMist Hybrid System to BeSpoke Pharmaceuticals, a 503B product manufacturer in Nevada, valued at over $200,000. These deals highlight TOMI's strategic growth and market reach in the Life Sciences sector, underscoring their innovation and potential for long-term growth.
TOMI Environmental Solutions, a global leader in disinfection technology, has announced cost reduction efforts aimed at achieving long-term profitability. The company plans to reduce executive compensation by 30% and cut external consulting fees, targeting a 30% reduction in operational cash use, approximately $500,000, by the end of 2024. Despite these cuts, TOMI will invest in expanding its sales team and global distribution network.
Key business updates include the successful installation of multiple Custom Engineered Systems (CES) expected to generate around $600,000 starting in 2025. TOMI is also in the final stages of securing a $450,000 CES contract with a prominent U.S. cell and gene therapy facility. The company is optimistic about securing new contracts, anticipating an increase in iHP Corporate Services revenue and ongoing negotiations with four major decontamination manufacturers.
Additionally, TOMI has signed a distribution deal with India's STS Technocrat and made its first sale under a Vizient contract, promoting its SteraMist technology.
TOMI Environmental Solutions (NASDAQ: TOMZ) announced its Q1 2024 financial results, reporting total net revenue of $1.1 million, a decrease from $1.58 million in Q1 2023. The company's gross margin improved to 60.2%, while operating loss increased to $1.23 million. Net loss for the quarter was $1.31 million or $0.07 per share. Significant developments include a $2 million order from the Department of Homeland Security for 16 SteraMist systems and a $600,000 contract with a California life sciences company. Additionally, the company submitted a proposal for a $3 million grant from the Department of Defense. The sales backlog at the end of Q1 2024 was $900,000, expected to be recognized in subsequent quarters.
TOMI Environmental Solutions, Inc. will discuss its first-quarter 2024 financial results on May 15, 2024, after market close. The company specializes in disinfection and decontamination solutions using its patented Binary Ionization Technology platform. TOMI will host a conference call to review the results at 4:30 p.m. ET.
FAQ
What is the current stock price of TOMI Environmental Solutions (TOMZ)?
What is the market cap of TOMI Environmental Solutions (TOMZ)?
What does TOMI Environmental Solutions specialize in?
What is Binary Ionization Technology® (BIT™)?
What sectors use TOMI's products?
What recent achievements has TOMI made?
How is TOMI expanding its market presence?
What financial strategies is TOMI implementing?
Where can I find more information about TOMI?
What is the significance of TOMI's collaboration with DARPA?
What are the primary components of the SteraMist® product line?
How is TOMI contributing to global health?
